Previous studies have identified therapy-induced, host-mediated mechanisms that may explain resistance to various cancer treatment modalities.22 23 To characterize the host-mediated response to ICI therapy, we first asked whether anti-PD1 treatment induces a systemic host response that promotes tumor cell aggressiveness. The gene discussed is PDCD1; the disease is neoplasm.